BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: De la Herrán-Arita AK, Guerra-Crespo M, Drucker-Colín R. Narcolepsy and orexins: an example of progress in sleep research. Front Neurol 2011;2:26. [PMID: 21541306 DOI: 10.3389/fneur.2011.00026] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 De la Herrán-Arita AK, García-García F. Current and emerging options for the drug treatment of narcolepsy. Drugs 2013;73:1771-81. [PMID: 24122734 DOI: 10.1007/s40265-013-0127-y] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 3.1] [Reference Citation Analysis]
2 Shah S, Ren A, Fan D, Zhang Z, Zhao N, Yang X, Luo M, Wang W, Hu F, Rehman M, Badarneh O, Abbasi Q. Internet of Things for Sensing: A Case Study in the Healthcare System. Applied Sciences 2018;8:508. [DOI: 10.3390/app8040508] [Cited by in Crossref: 31] [Article Influence: 7.8] [Reference Citation Analysis]
3 De la Herrán-arita AK, Drucker-colín R. Models for narcolepsy with cataplexy drug discovery. Expert Opinion on Drug Discovery 2012;7:155-64. [DOI: 10.1517/17460441.2012.651454] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
4 De la Herrán-arita AK, Equihua-benítez AC, Drucker-colín R. Treatment of cataplexy. Expert Opinion on Orphan Drugs 2013;1:199-210. [DOI: 10.1517/21678707.2013.765359] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
5 Madaan P, Behl T, Sehgal A, Singh S, Sharma N, Yadav S, Kaur S, Bhatia S, Al-harrasi A, Abdellatif AAH, Ashraf GM, Abdel-daim MM, Dailah HG, Anwer MK, Bungau S. Exploring the Therapeutic Potential of Targeting Purinergic and Orexinergic Receptors in Alcoholic Neuropathy. Neurotox Res. [DOI: 10.1007/s12640-022-00477-8] [Reference Citation Analysis]
6 Sivakumaran S, Agakov F, Theodoratou E, Prendergast JG, Zgaga L, Manolio T, Rudan I, McKeigue P, Wilson JF, Campbell H. Abundant pleiotropy in human complex diseases and traits. Am J Hum Genet 2011;89:607-18. [PMID: 22077970 DOI: 10.1016/j.ajhg.2011.10.004] [Cited by in Crossref: 345] [Cited by in F6Publishing: 303] [Article Influence: 34.5] [Reference Citation Analysis]
7 De la Herrán-Arita AK, García-García F. Narcolepsy as an immune-mediated disease. Sleep Disord 2014;2014:792687. [PMID: 24551456 DOI: 10.1155/2014/792687] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
8 Kovalzon VM, Zavalko IM. The neurochemistry of the sleep-wakefulness cycle and Parkinson’s disease. Neurochem J 2013;7:171-83. [DOI: 10.1134/s1819712413030069] [Cited by in Crossref: 5] [Article Influence: 0.6] [Reference Citation Analysis]
9 Gotter AL, Webber AL, Coleman PJ, Renger JJ, Winrow CJ. International Union of Basic and Clinical Pharmacology. LXXXVI. Orexin Receptor Function, Nomenclature and Pharmacology. Pharmacol Rev 2012;64:389-420. [DOI: 10.1124/pr.111.005546] [Cited by in Crossref: 114] [Cited by in F6Publishing: 107] [Article Influence: 11.4] [Reference Citation Analysis]
10 Spada J, Sander C, Burkhardt R, Häntzsch M, Mergl R, Scholz M, Hegerl U, Hensch T. Genetic association of objective sleep phenotypes with a functional polymorphism in the neuropeptide S receptor gene. PLoS One 2014;9:e98789. [PMID: 24896296 DOI: 10.1371/journal.pone.0098789] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
11 Modestino EJ, Winchester J. A retrospective survey of childhood ADHD symptomatology among adult narcoleptics. J Atten Disord 2013;17:574-82. [PMID: 23548870 DOI: 10.1177/1087054713480033] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 4.4] [Reference Citation Analysis]
12 Chaplin JE, Szakács A, Hallböök T, Darin N. The development of a health-related quality-of-life instrument for young people with narcolepsy: NARQoL-21. Health Qual Life Outcomes 2017;15:135. [PMID: 28676060 DOI: 10.1186/s12955-017-0707-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
13 Volta M, Lavdas AA, Obergasteiger J, Überbacher C, Picard A, Pramstaller PP, Hicks AA, Corti C. Elevated levels of alpha-synuclein blunt cellular signal transduction downstream of Gq protein-coupled receptors. Cell Signal 2017;30:82-91. [PMID: 27871937 DOI: 10.1016/j.cellsig.2016.11.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
14 Murphy P, Moline M, Mayleben D, Rosenberg R, Zammit G, Pinner K, Dhadda S, Hong Q, Giorgi L, Satlin A. Lemborexant, A Dual Orexin Receptor Antagonist (DORA) for the Treatment of Insomnia Disorder: Results From a Bayesian, Adaptive, Randomized, Double-Blind, Placebo-Controlled Study. J Clin Sleep Med 2017;13:1289-99. [PMID: 29065953 DOI: 10.5664/jcsm.6800] [Cited by in Crossref: 50] [Cited by in F6Publishing: 43] [Article Influence: 10.0] [Reference Citation Analysis]
15 Kumar S, Behl T, Sehgal A, Singh S, Sharma N, Bhatia S, Al-Harassi A, Abdel-Daim MM, Bungau S. Exploring the Role of Orexinergic Neurons in Parkinson's Disease. Neurotox Res 2021. [PMID: 34495449 DOI: 10.1007/s12640-021-00411-4] [Reference Citation Analysis]
16 Gotter AL, Roecker AJ, Hargreaves R, Coleman PJ, Winrow CJ, Renger JJ. Orexin receptors as therapeutic drug targets. Prog Brain Res 2012;198:163-88. [PMID: 22813974 DOI: 10.1016/B978-0-444-59489-1.00010-0] [Cited by in Crossref: 71] [Cited by in F6Publishing: 24] [Article Influence: 7.1] [Reference Citation Analysis]
17 Hayakawa K, Hirosawa M, Tabei Y, Arai D, Tanaka S, Murakami N, Yagi S, Shiota K. Epigenetic switching by the metabolism-sensing factors in the generation of orexin neurons from mouse embryonic stem cells. J Biol Chem 2013;288:17099-110. [PMID: 23625921 DOI: 10.1074/jbc.M113.455899] [Cited by in Crossref: 53] [Cited by in F6Publishing: 36] [Article Influence: 5.9] [Reference Citation Analysis]
18 Berhe DF, Gebre AK, Assefa BT. Orexins role in neurodegenerative diseases: From pathogenesis to treatment. Pharmacol Biochem Behav 2020;194:172929. [PMID: 32315694 DOI: 10.1016/j.pbb.2020.172929] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]